Protein in blood ‘may reveal rare form of Alzheimer’s 10 years before symptoms’

Discovery could lead to earlier detection of the disease and help slow its progress with drugs

Scientists have discovered blood markers that could help identify people who have a rare, inherited form of Alzheimer's. PA

A rare, inherited form of Alzheimer’s disease could be identified in blood markers a decade before symptoms begin to appear, scientists have said.

Glial fibrillary acidic protein, or GFAP, can appear in blood samples of people who are in the very early stages of the neurodegenerative disease, researchers at the Karolinska Institutet in Sweden found.

The findings, published in the journal Brain, could lead to the earlier detection of the disease and allow it to be slowed down with drugs.

“Our results suggest that GFAP, a presumed biomarker for activated immune cells in the brain, reflects changes in the brain due to Alzheimer’s disease that occur before the accumulation of tau protein and measurable neuronal damage,” said lead author Charlotte Johansson, a doctoral student at Karolinska's Department of Neurobiology, Care Sciences and Society.

Alzheimer’s disease is a progressive condition with symptoms developing gradually over many years, eventually becoming more severe.

Nerve cells in the brain degenerate as a result of the abnormal accumulation of two types of proteins known as beta-amyloid and tau.

The first sign of the disease is usually minor memory problems.

New drug appears to improve Alzheimer’s — in pictures

As more nerve cells become damaged, speech becomes affected.

In the vast majority of cases — more than 99 in 100 — Alzheimer’s is not inherited, but in rarer types, there may be a strong genetic link.

In these cases, people with a parent with Alzheimer’s caused by a mutation have a 50 per cent risk of developing the disease themselves.

For their study, the researchers analysed 164 blood plasma samples from 33 mutation carriers and 42 relatives without it.

The researchers said their results showed “clear changes” in the samples of those who carried the mutations.

“The first change we observed was an increase in GFAP … approximately 10 years before the first disease symptoms,” said study author Caroline Graff, professor at Karolinska's Department of Neurobiology, Care Sciences and Society.

“This was followed by increased concentrations of P-tau181 and, later, NfL (neurofilament light protein), which we already know is directly associated with the extent of neuronal damage in the Alzheimer’s brain.

“This finding about GFAP improves the chances of early diagnosis.”